Neoadjuvant therapy is poorly adopted among patients submitted to radical cystectomy (RC) for urothelial carcinoma of the bladder. Recently, pembrolizumab has been tested in the neoadjuvant setting with promising oncological results in an open-label phase II study. However, there is a lack of data regarding the safety of such approach in terms of postoperative outcomes after RC. We tried to evaluate these outcomes in a population of patients treated with RC at a single tertiary care referral center. METHODS: We evaluated 802 patients treated with RC between 2010 and 2018. Among those, we identified 61 patients who received neoadjuvant therapy according to the MVAC scheme vs. 52 patients treated with pembrolizumab vs. 689 patients who did not receive any neoadjuvant treatment. Descriptive statistics showed the differences in clinical features of patients across the three groups. Logistic regression analyses evaluated the effect of neoadjuvant regimen on the risk of post-op complications after RC.
INTRODUCTION AND OBJECTIVES:
Neoadjuvant therapy is poorly adopted among patients submitted to radical cystectomy (RC) for urothelial carcinoma of the bladder. Recently, pembrolizumab has been tested in the neoadjuvant setting with promising oncological results in an open-label phase II study. However, there is a lack of data regarding the safety of such approach in terms of postoperative outcomes after RC. We tried to evaluate these outcomes in a population of patients treated with RC at a single tertiary care referral center.
METHODS: We evaluated 802 patients treated with RC between 2010 and 2018. Among those, we identified 61 patients who received neoadjuvant therapy according to the MVAC scheme vs. 52 patients treated with pembrolizumab vs. 689 patients who did not receive any neoadjuvant treatment. Descriptive statistics showed the differences in clinical features of patients across the three groups. Logistic regression analyses evaluated the effect of neoadjuvant regimen on the risk of post-op complications after RC.
RESULTS: Median patient age was higher in the no-adjuvant group compared to MVAC and pembrolizumab (70 vs. 63.9 vs. 68 .1 yrs; p<0.001). Similarly, comorbidities significantly differed among the three groups (CCI 1 vs. 0 vs. 0; p<0.001). Orthotopic neobladder was more represented in the MVAC and in the pembrolizumab groups (24.1% vs. 37.7% vs. 46.2%). Median operative time did not significantly differ among the three groups (379 vs. 401 vs. 372 min, p[0.09) and postoperative high-grade complications (Clavien!3) did not differ between the examined groups. However, when looking at the single complications, we observed a significant difference in the rates of post-op ileus (6.1% vs. 4.9% vs. 19.2%; p<0.01) and urinary complications treated with percutaneous nephrostomy (3.6% vs. 6.6% vs. 15.4%; p<0.01). In multivariable logistic regression analyses, patients who received pembrolizumab were 3-fold more likely to achieve pT0 after RC compared to no-adjuvant (p<0.01), while MVAC failed to achieve independent predictor status (p[0.8). Multivariable logistic regression analyses failed to demonstrate the role of any type of neoadjuvant treatment on the risk of postoperative complications.
CONCLUSIONS: Neoadjuvant treatments available prior to RC can be safely administered. In particular, neoadjuvant pembrolizumab results in a higher rate of pT0 after RC, with no major toxicity added in terms of peri-and post-operative complications.
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MP32-07 BLADDER CANCER PATIENTS WITHOUT PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY EXPERIENCE LOWER SURVIVAL RATES THAN RADICAL CYSTECTOMY ALONE
John Pfail*, François Audenet, Alberto Martini, Kyrollis Attalla, Nikhil Waingankar, Matthew Galsky, John Sfakianos, New York, NY INTRODUCTION AND OBJECTIVES: Approximately, 30-40% of bladder cancer patients treated with neoadjuvant chemotherapy (NAC) will have a pathologic complete response. Delayed radical cystectomy (RC) may compromise the outcome of patients not sensitive to NAC. The aim of our study was to compare overall survival (OS) between patients responsive and nonresponsive to NAC at time of RC to those who underwent RC alone.
METHODS: The National Cancer Data Base was queried for patients who underwent RC with or without NAC for MIBC from 2004-2015. Covariates including age, sex, race, insurance, income, education, county, facility type, Charlson-Deyo comorbidity index, and clinical size (cT) were balanced using inverse probability of treatment weighting (IPTW). 6-month conditional landmark analyses, from the time of surgery, along with Cox proportional hazards models were conducted to analyze differences in OS. All models were stratified by pathological stage.
RESULTS: 11,287 were included in our analysis (Table 1 ). The 5-year IPTW-adjusted rates of OS were 44.7% (95% CI: 43.5 -45.9, p<0.001) for NACþRC vs 38.4% (95% CI: 37.4 -49.4, p<0.001) for RC alone (HR: 0.864, 95% CI: 0.832 -0.896, p<0.001). The 6-month conditional landmark analysis revealed an increased risk of death (HR: 1.31 95% CI 1.23 -1.39 and HR: 1.22 95% CI 1.11 -1.35; both p<0.001) and decreased median OS (23.5 vs. 32.2 mos.; p<0.001 and 19.3 vs. 22.3 mos.; p[0.218) in patients treated with NACþRC compared to RC alone, for pT3 and pT4 disease, respectively (Figure 1) . CONCLUSIONS: Patients with pT3 or pT4 disease after NAC experienced a significant increased risk of death and decrease in median OS when compared to pathological stage-matched patients who underwent RC alone. Given the possible delay to definitive treatment by RC, for patients nonresponsive to NAC, further research is warranted to accurately determine patient selection for NAC.
INTRODUCTION AND OBJECTIVES: Pathologic complete response after neoadjuvant chemotherapy (NAC) is associated with better overall (OS) and recurrence free survival (RFS). Whereas, delay in cystectomy has been reported to be associated with worse outcomes. We sought to better understand the consequences of administering NAC to those who did not benefit from it by comparing oncological outcomes to patients who were eligible for NAC but underwent immediate cystectomy.
METHODS: Retrospective review of 322 patients with with muscle-invasive bladder cancer who underwent radical cystectomy between 2001-2017. Non-responders (NR) to NAC on final pathology constituted the group of interest. Patients who underwent immediate cystectomy (IC) but were NAC eligible constituted the comparison group. Only those with ! pT2 were included in the analysis. Recurrence rates and patterns were compared between both groups. RFS, cancer-specific survival (CSS) and OS were estimated using the Kaplan-Meier method.
RESULTS: A total of 132 (41%) received NAC, of which 68 (51.5%) had no pathologic response. Whereas, 154 patients (! pT2) did not receive NAC and underwent IC. Patients in the NR group were younger (67 vs 75 years, p <0.00001) compared to those who had IC, however baseline GFR was similar between groups (62 for both, p [ 0.52). Pathologic tumor staging, nodal involvement, surgical margin status and lymphovascular invasion rates were similar in both groups (p >0.05, see table).
Median follow up for surviving patients was 32.5 months. At last follow up, recurrence was higher in NR patients (59%) than IC (42%, p [ 0.02), however both had similar distribution of disease recurrence as seen in the table. Non-responders had worse RFS (56% and 33% vs. 62% and 55%, p[ 0.03) at 1 and 2 years but similar CSS (79% and 55% vs. 81% and 56%, p[0.75) and OS (68% and 36% vs. 68% and 38%, p[ 0.5) compared to those in the IC group at 1 and 3 years.
CONCLUSIONS: Patients with ! pT2 who failed NAC had higher recurrence rates than those who had forgone NAC for immediate cystectomy. Our study demonstrates the opportunity for developing reliable biomarkers to predict benefit from NAC or improve surveillance protocols for those receiving NAC in order to minimize delay to cystectomy.
